Blocking TNFα with Etanercept, a human tumor necrosis factor receptor (TNFR) p75 Fc fusion protein, resulted in lower A1C levels and increased insulin production in children with early-onset T1D, suggesting that this treatment may preserve β-cell function [127]. The gene discussed is TNF; the disease is type 1 diabetes mellitus.